Literature DB >> 27559705

Polycystic ovary syndrome and environmental toxins.

Aleksandra Zofia Rutkowska1, Evanthia Diamanti-Kandarakis2.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common, heterogeneous, and multifactorial endocrine disorder in premenopausal women. The pathophysiology of this endocrinopathy is still unclear; however, the heterogeneity of its features within ethnic races, geographic location, and families suggests that environment and lifestyle are of prime importance. This work is mainly focused on the possible role of the most common and studied environmental toxins for this syndrome in the pathogenesis of PCOS. Plasticizers, such as bisphenol A (BPA) or phthalates, which belong to the categories of endocrine disrupting chemicals (EDCs) and advanced glycation end products (AGEs), affect humans' health in everyday, industrialized life; therefore special attention should be paid to such exposure. Timing of exposure to EDCs is crucial for the intensity of adverse health effects. It is now evident that fetuses, infants, and/or young children are the most susceptible groups, especially in the early development periods. Prenatal exposure to EDCs that mimic endogenous hormones may contribute to the altered fetal programming and in consequence lead to PCOS and other adverse health effects, potentially transgenerationally. Acute or prolonged exposure to EDCs and AGEs through different life cycle stages may result in destabilization of the hormonal homeostasis and lead to disruption of reproductive functions. They may also interfere with metabolic alterations such as obesity, insulin resistance, and compensatory hyperinsulinemia that can exacerbate the PCOS phenotype and contribute to PCOS consequences such as type 2 diabetes and cardiovascular disease. Since wide exposure to environmental toxins and their role in the pathophysiology of PCOS are supported by extensive data derived from diverse scientific models, protective strategies and strong recommendations should be considered to reduce human exposure to protect present and future generations from their adverse health effects.
Copyright © 2016 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Polycystic ovary syndrome; advanced glycation end products; bisphenol A; endocrine disrupting chemicals

Mesh:

Substances:

Year:  2016        PMID: 27559705     DOI: 10.1016/j.fertnstert.2016.08.031

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  23 in total

Review 1.  Blaming the Brain for Obesity: Integration of Hedonic and Homeostatic Mechanisms.

Authors:  Hans-Rudolf Berthoud; Heike Münzberg; Christopher D Morrison
Journal:  Gastroenterology       Date:  2017-02-10       Impact factor: 22.682

Review 2.  Polycystic ovary syndrome throughout a woman's life.

Authors:  José Bellver; Luis Rodríguez-Tabernero; Ana Robles; Elkin Muñoz; Francisca Martínez; José Landeras; Juan García-Velasco; Juan Fontes; Mónica Álvarez; Claudio Álvarez; Belén Acevedo
Journal:  J Assist Reprod Genet       Date:  2017-09-27       Impact factor: 3.412

Review 3.  Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.

Authors:  Héctor F Escobar-Morreale
Journal:  Nat Rev Endocrinol       Date:  2018-03-23       Impact factor: 43.330

4.  Environmental risk factors for endometriosis: A critical evaluation of studies and recommendations from the epidemiologic perspective.

Authors:  Kristen Upson
Journal:  Curr Epidemiol Rep       Date:  2020-08-18

5.  Acetate restores hypothalamic-adipose kisspeptin status in a rat model of PCOS by suppression of NLRP3 immunoreactivity.

Authors:  Kehinde S Olaniyi; Stephanie E Areloegbe; Mosunmola B Oyeleke
Journal:  Endocrine       Date:  2022-09-16       Impact factor: 3.925

Review 6.  Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome.

Authors:  Simon Alesi; Carolyn Ee; Lisa J Moran; Vibhuti Rao; Aya Mousa
Journal:  Adv Nutr       Date:  2022-08-01       Impact factor: 11.567

Review 7.  Epigenetic Modifications Associated with Exposure to Endocrine Disrupting Chemicals in Patients with Gestational Diabetes Mellitus.

Authors:  Mateusz Kunysz; Olimpia Mora-Janiszewska; Dorota Darmochwał-Kolarz
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

8.  Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome.

Authors:  Lili Hu; Li Ma; Xinyi Xia; Tao Ying; Minzhi Zhou; Shuhua Zou; Haoyong Yu; Jun Yin
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

9.  Anti-Müllerian hormone (AMH) in the Diagnosis of Menstrual Disturbance Due to Polycystic Ovarian Syndrome.

Authors:  Ali Abbara; Pei Chia Eng; Maria Phylactou; Sophie A Clarke; Tia Hunjan; Rachel Roberts; Sunitha Vimalesvaran; George Christopoulos; Rumana Islam; Kate Purugganan; Alexander N Comninos; Geoffrey H Trew; Rehan Salim; Artsiom Hramyka; Lisa Owens; Tom Kelsey; Waljit S Dhillo
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-26       Impact factor: 5.555

10.  A Single Bout of Electroacupuncture Remodels Epigenetic and Transcriptional Changes in Adipose Tissue in Polycystic Ovary Syndrome.

Authors:  Milana Kokosar; Anna Benrick; Alexander Perfilyev; Emma Nilsson; Thomas Källman; Claes Ohlsson; Charlotte Ling; Elisabet Stener-Victorin
Journal:  Sci Rep       Date:  2018-01-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.